The company’s stock price has dropped to around $1.38 per share after its IPF therapy trial was stopped for safety.

Cantor Fitzgerald reinstated coverage of Pliant Therapeutics (PLRX) with a Neutral rating and no price target The company is discontinuing the ...

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel ...

The new chief medical officer of the Pulmonary Fibrosis Foundation speaks about patients in rural areas, research ...

Pliant Therapeutics shares dropped 52% to $1.64, after the company said it was discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis. The stock hit its 52-week ...

The trial, dubbed BEACON-IPF, was assessing the biotech’s lead candidate, an oral small molecule called bexotegrast. The ...

Pliant Therapeutics (PLRX) announced that following a prespecified data review and recommendation by the trial’s independent Data Safety ...

The following is a summary of "Quality of life in idiopathic pulmonary fibrosis in Latin American countries," published in ...

The UK IPF Registry has provided new insights into the evolving landscape of idiopathic pulmonary fibrosis management.

Learn about idiopathic pulmonary fibrosis, its symptoms, diagnosis, and treatment options for managing this lung disease.

CS014 has shown the ability to reverse scarring and ease blood vessel remodeling in a preclinical model of pulmonary arterial ...